Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure
Open Access
- 16 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (2) , 950-961
Abstract
Aims: Approximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs)]. We investigated what proportion of patients are on optimal doses prior to discharge and how many might be eligible for initiation of sacubitril–valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2Is). Methods and results: Between 2012 and 2017, 1277 patients admitted with suspected heart failure were enrolled at a single hospital serving a local community around Kingston upon Hull, UK. Eligibility for sacubitril–valsartan or SGLT2I was based on entry criteria for the PIONEER-HF, DAPA-HF, and EMPEROR-Reduced trials. Four hundred fifty-five patients had HeFREF with complete data on renal function, heart rate, and systolic blood pressure (SBP) prior to discharge. Eighty-three per cent of patients were taking an ACE-I or ARB, 85% a BB, and 63% an MRA at discharge. More than 60% of patients were eligible for sacubitril–valsartan and >70% for SGLT2I. Among those not already receiving a prescription, 37%, 28%, and 49% were eligible to start ACE-I or ARB, BB, and MRA, respectively. Low SBP (≤105 mmHg) was the most frequent explanation for failure to initiate or up-titrate therapy. Conclusions: Most patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge. A hospital admission may be a common missed opportunity to improve treatment for patients with HeFREF.Keywords
Funding Information
- British Heart Foundation Centre of Research Excellence (RE/18/6/34217)
This publication has 29 references indexed in Scilit:
- Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment TrialThe American Journal of Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Initiation of Sacubitril/Valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early After Discharge: Primary Results of the Randomised TRANSITION StudyEuropean Journal of Heart Failure, 2019
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureNew England Journal of Medicine, 2019
- Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron DeficiencyJAMA, 2017
- Drugs That May Cause or Exacerbate Heart FailureCirculation, 2016
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysisEuropean Heart Journal, 2013
- Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic CardiomyopathyJACC: Heart Failure, 2013
- Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved OutcomesCirculation, 2007